載入...
Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K(+)) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with...
Na minha lista:
| 主要作者: | |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3090287/ https://ncbi.nlm.nih.gov/pubmed/21573085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S10469 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|